Table 1.
Dilution and sources of antibodies used in immunohistochemistry and in situ hybridization
| Antigen | Dilution | Vendor | Antigen | Dilution | Vendor |
|---|---|---|---|---|---|
| ALK | 1:40 | Dako, Carpinteria, CA | CD138 | 1:60 | abD Serotec, Taleigh, NC |
| BCL-6 | 1:10 | Biocare Medical, Concord, CA | EBV | 1:300 | Dako |
| Bob-1 | 1:60 | Cell Marque, Rocklin, CA | EMA | 1:2 | Dako |
| CD2 | 1:20 | Novocastra | HMB-45 | 1:2 | Dako |
| CD3 | 1:50 | Lab Vision, Fremont, CA | Kappa (IHC) | 1:500 | Biocare Medical |
| CD4 | 1:20 | Biocare Medical | Kappa (ISH) | N/A | ZytoVision, Germany |
| CD5 | 1:50 | Biocare Medical | Lambda (IHC) | 1:35 | Biocare Medical |
| CD7 | 1:40 | Biocare Medical | Lambda (ISH) | N/A | ZytoVision |
| CD8 | 1:80 | Biocare Medical | LANA | 1:25 | UCSD, San Diego, CA |
| CD10 | 1:40 | Thermo Scientific, Fremont, CA | Lysozyme | 1:150 | Invitrogen, Camarillo, CA |
| CD19 | 1:400 | Biocare Medical | Mart-1 | 1:100 | Dako |
| CD20 | 1:250 | Dako | MIB-1 | 1:50 | Dako |
| CD30 | 1:20 | Dako | MPO | 1:10,000 | Dako |
| CD34 | 1:30 | Becton Dickinson, San Jose, CA | MUM1 | 1:50 | Dako |
| CD43 | 1:60 | Dako | Oct-2 | 1:50 | Invitrogen, Carlsbad, CA |
| CD45 | 1:100 | Dako | Pan-cytokeratin | Cocktail | Dako |
| CD45RA | 1:40 | Dako | PAX-5 | 1:40 | Biocare Medical |
| CD56 | 1:10 | Biocare Medical | S100 | 1:20 | Invitrogen, Camarillo, CA |
| CD68 | 1:15 | Dako | TdT | 1:25 | Dako |
| CD79a | 1:50 | Dako | TIA-1 | 1:100 | Biocare Medical |
ALK: anaplastic lymphoma kinase; N: negative; P: positive; EBV: Epstein-Barr virus; EMA: epithelial membrane antigen; IHC: immunohistochemistry; ISH: in situ hybridization; LANA: human herpes virus -8 (HHV-8) latency associated nuclear antigen; Pan-cytokeratin cocktail: AE1/AE3(1:30) plus MNF116 (1:30); TdT: terminal deoxynucleotidyl trans-ferase; TIA-1: T-cell intracellular antigen 1.